for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Menlo Therapeutics Inc

MNLO.OQ

Latest Trade

4.76USD

Change

-0.26(-5.18%)

Volume

114,306

Today's Range

4.60

 - 

5.21

52 Week Range

2.70

 - 

11.92

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
5.02
Open
5.01
Volume
114,306
3M AVG Volume
1.17
Today's High
5.21
Today's Low
4.60
52 Week High
11.92
52 Week Low
2.70
Shares Out (MIL)
23.95
Market Cap (MIL)
120.24
Forward P/E
-1.61
Dividend (Yield %)
--

Next Event

Menlo Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference

Latest Developments

More

Menlo Therapeutics Posts Q2 Loss Per Share Of $0.69

Menlo Therapeutics Reports Qtrly Net Loss Per Share $0.81

Menlo Therapeutics Reports Fourth Quarter And Full Year 2018 Financial Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Menlo Therapeutics Inc

Menlo Therapeutics Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of serlopitant for the treatment of pruritus (itch) associated with dermatologic conditions, such as atopic dermatitis, psoriasis and prurigo nodularis. It is also evaluating the use of serlopitant for the treatment of refractory chronic cough. The Company’s serlopitant is a small molecule, highly selective NK1-R antagonist. It is developing serlopitant as an once-daily oral tablet therapy. The Company has completed Phase II clinical trials in pruritus associated with atopic dermatitis.

Industry

Biotechnology & Drugs

Contact Info

200 Cardinal Way Fl 2

+1.650.4861416

http://www.menlotherapeutics.com/

Executive Leadership

Steven L. Basta

President, Chief Executive Officer, Director

Kristine M. Ball

Senior Vice President - Corporate Strategy, Chief Financial Officer

Paul S. Kwon

Chief Scientific Officer

Elisabeth A. Sandoval

Director

Paul L. Berns

Independent Director

Key Stats

2.20 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2017

-5.690

2018

-2.370

2019(E)

-3.122
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
1.18
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.70
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-50.46
Return on Equity (TTM)
-46.78

Latest News

BRIEF-Menlo Therapeutics Reports Qtrly Loss Per Share $0.72

* MENLO THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Menlo Therapeutics Says Japanese Phase 2 Trial Of Serlopitant Halted

* MENLO THERAPEUTICS - CO'S PARTNERS FOR COMMERCIALIZATION OF SERLOPITANT IN JAPAN, INFORMED DECISION TO HALT JAPANESE PHASE 2 CLINICAL TRIAL OF SERLOPITANT

BRIEF-Menlo Therapeutics Reports Q4 Loss Of $1.80 Per Share

* MENLO THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Novo Holdings Reports 5.05 Pct Passive Stake In Menlo Therapeutics

* NOVO HOLDINGS A/S REPORTS 5.05 PERCENT PASSIVE STAKE IN MENLO THERAPEUTICS INC, AS OF JANUARY 29, 2018 - SEC FILING Source text: (http://bit.ly/2nSBUJu) Further company coverage:

BRIEF-Menlo Therapeutics Now Sees IPO Of 6.5 Mln Shares Of Common Stock Priced Between $16 And $17 Per Share

* MENLO THERAPEUTICS INC NOW SEES IPO OF 6.5 MILLION SHARES OF COMMON STOCK PRICED BETWEEN $16.00 AND $17.00 PER SHARE - SEC FILING

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up